<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">33609255</PMID><DateCompleted><Year>2023</Year><Month>01</Month><Day>27</Day></DateCompleted><DateRevised><Year>2023</Year><Month>02</Month><Day>02</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1559-0267</ISSN><JournalIssue CitedMedium="Internet"><Volume>64</Volume><Issue>1</Issue><PubDate><Year>2023</Year><Month>Feb</Month></PubDate></JournalIssue><Title>Clinical reviews in allergy &amp; immunology</Title><ISOAbbreviation>Clin Rev Allergy Immunol</ISOAbbreviation></Journal><ArticleTitle>A Review of Persistent Post-COVID Syndrome (PPCS).</ArticleTitle><Pagination><StartPage>66</StartPage><EndPage>74</EndPage><MedlinePgn>66-74</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1007/s12016-021-08848-3</ELocationID><Abstract><AbstractText>Persistent post-COVID syndrome, also referred to as long COVID, is a pathologic entity, which involves persistent physical, medical, and cognitive sequelae following COVID-19, including persistent immunosuppression as well as pulmonary, cardiac, and vascular fibrosis. Pathologic fibrosis of organs and vasculature leads to increased mortality and severely worsened quality of life. Inhibiting transforming growth factor beta (TGF-&#x3b2;), an immuno- and a fibrosis modulator, may attenuate these post-COVID sequelae. Current preclinical and clinical efforts are centered on the mechanisms and manifestations of COVID-19 and its presymptomatic and prodromal periods; by comparison, the postdrome, which occurs in the aftermath of COVID-19, which we refer to as persistent post-COVID-syndrome, has received little attention. Potential long-term effects from post-COVID syndrome will assume increasing importance as a surge of treated patients are discharged from the hospital, placing a burden on healthcare systems, patients' families, and society in general to care for these medically devastated COVID-19 survivors. This review explores underlying mechanisms and possible manifestations of persistent post-COVID syndrome, and presents a framework of strategies for the diagnosis and management of patients with suspected or confirmed persistent post-COVID syndrome.</AbstractText><CopyrightInformation>&#xa9; 2021. The Author(s), under exclusive licence to Springer Science+Business Media, LLC part of Springer Nature.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Oronsky</LastName><ForeName>Bryan</ForeName><Initials>B</Initials><Identifier Source="ORCID">0000-0002-3940-6329</Identifier><AffiliationInfo><Affiliation>EpicentRx Inc, La Jolla, 11099 North Torrey Pines Road, Suite 160, La Jolla, CA, 92037, USA. boronsky@epicentrx.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Larson</LastName><ForeName>Christopher</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>EpicentRx Inc, La Jolla, 11099 North Torrey Pines Road, Suite 160, La Jolla, CA, 92037, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hammond</LastName><ForeName>Terese C</ForeName><Initials>TC</Initials><AffiliationInfo><Affiliation>Providence St. John's Health Center, Santa Monica, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Oronsky</LastName><ForeName>Arnold</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>InterWest Partners, Los Altos, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kesari</LastName><ForeName>Santosh</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Providence St. John's Health Center, Santa Monica, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lybeck</LastName><ForeName>Michelle</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>EpicentRx Inc, La Jolla, 11099 North Torrey Pines Road, Suite 160, La Jolla, CA, 92037, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Reid</LastName><ForeName>Tony R</ForeName><Initials>TR</Initials><AffiliationInfo><Affiliation>EpicentRx Inc, La Jolla, 11099 North Torrey Pines Road, Suite 160, La Jolla, CA, 92037, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2021</Year><Month>02</Month><Day>20</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Clin Rev Allergy Immunol</MedlineTA><NlmUniqueID>9504368</NlmUniqueID><ISSNLinking>1080-0549</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018450" MajorTopicYN="N">Disease Progression</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007165" MajorTopicYN="N">Immunosuppression Therapy</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000094024" MajorTopicYN="Y">Post-Acute COVID-19 Syndrome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011788" MajorTopicYN="N">Quality of Life</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">COVID-19</Keyword><Keyword MajorTopicYN="N">Immunology</Keyword><Keyword MajorTopicYN="N">SARS-CoV-2</Keyword><Keyword MajorTopicYN="N">TGF-&#x3b2;</Keyword></KeywordList><CoiStatement>EpicentRx, Inc., funds research of the AdAPT-001 product. Authors B.O., C.L. and T.R. are employed by EpicentRx, Inc.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="accepted"><Year>2021</Year><Month>1</Month><Day>28</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2021</Year><Month>2</Month><Day>21</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>1</Month><Day>26</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2021</Year><Month>2</Month><Day>20</Day><Hour>12</Hour><Minute>6</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2021</Year><Month>2</Month><Day>20</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">33609255</ArticleId><ArticleId IdType="pmc">PMC7896544</ArticleId><ArticleId IdType="doi">10.1007/s12016-021-08848-3</ArticleId><ArticleId IdType="pii">10.1007/s12016-021-08848-3</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Milne GJ, Xie S (2020)&#xa0;The effectiveness of social distancing in mitigating COVID-19 spread: a modelling analysis. medRxiv. 03.20.20040055</Citation></Reference><Reference><Citation>Misra DP, Agarwal V, Gasparyan AY&#xa0;et al (2020) Rheumatologists&#x2019; perspective on coronavirus disease 19 (COVID-19) and potential therapeutic targets.&#xa0;Clin Rheumatol</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7145936</ArticleId><ArticleId IdType="pubmed">32277367</ArticleId></ArticleIdList></Reference><Reference><Citation>https://nypost.com/2020/03/13/coronavirus-survivors-may-suffer-from-reduced-lung-function/</Citation></Reference><Reference><Citation>Baud D, Qi X, Nielsen-Saines K, Musso D, Pomar L, Favre G (2020) Real estimates of mortality following COVID-19 infection [published online ahead of print, 2020 Mar 12].&#xa0;Lancet Infect Dis S1473&#x2013;3099(20)30195-X</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7118515</ArticleId><ArticleId IdType="pubmed">32171390</ArticleId></ArticleIdList></Reference><Reference><Citation>Mostel Z, Perl A, Marck M et al (2019) Post-sepsis syndrome - an evolving entity that afflicts survivors of sepsis. Mol Med 26(1):6. Published 31 Dec 2019</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6938630</ArticleId><ArticleId IdType="pubmed">31892321</ArticleId></ArticleIdList></Reference><Reference><Citation>Stam HJ, Stucki G, Bickenbach J (2020) Covid-19 and post intensive care syndrome: a call for action. J Rehabil Med Apr 15;52(4):jrm00044</Citation><ArticleIdList><ArticleId IdType="pubmed">32286675</ArticleId></ArticleIdList></Reference><Reference><Citation>Angus DC (2010) The lingering consequences of sepsis: a hidden public health disaster? JAMA Oct 27;304(16):1833-4</Citation><ArticleIdList><ArticleId IdType="pubmed">20978262</ArticleId></ArticleIdList></Reference><Reference><Citation>Hotchkiss RS, Monneret G, Payen D (2013) Sepsis-induced immunosuppression: from cellular dysfunctions to immunotherapy. Nat Rev Immunol 13:862&#x2013;874</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4077177</ArticleId><ArticleId IdType="pubmed">24232462</ArticleId></ArticleIdList></Reference><Reference><Citation>Bone RC (1996) Sir Isaac Newton, sepsis, SIRS, and CARS. Crit Care Med 24:1125&#x2013;1128</Citation><ArticleIdList><ArticleId IdType="pubmed">8674323</ArticleId></ArticleIdList></Reference><Reference><Citation>Sugimoto MA, Sousa LP, Pinho V, Perretti M, Teixeira MM (2016) Resolution of inflammation: what controls its onset?. Front Immunol 7:160. Published 2016 Apr 26</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4845539</ArticleId><ArticleId IdType="pubmed">27199985</ArticleId></ArticleIdList></Reference><Reference><Citation>Bozza FA, Salluh JI, Japiassu AM, Soares M, Assis EF, Gomes RN, Bozza MT, Castro-Faria-Neto HC, Bozza PT (2007) Cytokine profiles as markers of disease severity in sepsis: a multiplex analysis. Crit Care 11(2):R49</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2206478</ArticleId><ArticleId IdType="pubmed">17448250</ArticleId></ArticleIdList></Reference><Reference><Citation>Delano MJ, Ward PA (2016) The immune system's role in sepsis progression, resolution, and long-term outcome. Immunol Rev 274(1):330&#x2013;353</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5111634</ArticleId><ArticleId IdType="pubmed">27782333</ArticleId></ArticleIdList></Reference><Reference><Citation>Kell DB, Pretorius E (2018) To what extent are the terminal stages of sepsis, septic shock, systemic inflammatory response syndrome, and multiple organ dysfunction syndrome actually driven by a prion/amyloid form of fibrin?. Semin Thromb Hemost 44(3):224&#x2013;238</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6193370</ArticleId><ArticleId IdType="pubmed">28778104</ArticleId></ArticleIdList></Reference><Reference><Citation>Biradar V, Moran JL (2011) SIRS, Sepsis and Multiorgan Failure. In: Fitridge R, Thompson M, editors. Mechanisms of vascular disease: a reference book for vascular specialists [Internet]. Adelaide (AU): University of Adelaide Press 17. Available from: https://www.ncbi.nlm.nih.gov/books/NBK534275/</Citation><ArticleIdList><ArticleId IdType="pubmed">0</ArticleId></ArticleIdList></Reference><Reference><Citation>Hamers L, Kox M, Pickkers P (2015) Sepsis-induced immunoparalysis: mechanisms, markers, and treatment options. Minerva Anestesiol Apr;81(4):426-39. Epub 2014 May 30</Citation><ArticleIdList><ArticleId IdType="pubmed">24878876</ArticleId></ArticleIdList></Reference><Reference><Citation>Walton AH, Muenzer JT, Rasche D et al (2014) Reactivation of multiple viruses in patients with sepsis. PLoS One 9(2):e98819. Published 11 Jun 2014</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4053360</ArticleId><ArticleId IdType="pubmed">24919177</ArticleId></ArticleIdList></Reference><Reference><Citation>https://www.npr.org/sections/coronavirus-live-updates/2020/04/17/836747242/in-south-korea-a-growing-number-of-covid-19-patients-test-positive-after-recover</Citation></Reference><Reference><Citation>https://www.reuters.com/article/us-health-coronavirus-southkorea/south-korea-reports-more-recovered-coronavirus-patients-testing-positive-again-idUSKCN21V0JQ</Citation></Reference><Reference><Citation>Xu K1, Cai H, Shen Y, Ni Q, Chen Y, Hu S, Li J et al (2020) [Management of corona virus disease-19 (COVID-19): the Zhejiang experience].[Article in Chinese] Zhejiang Da Xue Xue Bao Yi Xue Ban Feb 21;49(1):0</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8800711</ArticleId><ArticleId IdType="pubmed">32391658</ArticleId></ArticleIdList></Reference><Reference><Citation>Shi H, Han X, Jiang N et al (2020) Radiological findings from 81 patients with COVID-19 pneumonia in Wuhan, China: a descriptive study. Lancet Infect Dis 20(4):425&#x2013;434</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7159053</ArticleId><ArticleId IdType="pubmed">32105637</ArticleId></ArticleIdList></Reference><Reference><Citation>Hosseiny M, Kooraki S, Gholamrezanezhad A, Reddy S, Myers L (2020)Radiology Perspective of Coronavirus Disease 2019 (COVID-19): Lessons From Severe Acute Respiratory Syndrome and Middle East Respiratory Syndrome. AJR Am J Roentgenol Feb 28:1-5</Citation><ArticleIdList><ArticleId IdType="pubmed">32108495</ArticleId></ArticleIdList></Reference><Reference><Citation>Russell B, Moss C, George G et al (2020) Associations between immune-suppressive and stimulating drugs and novel COVID-19-a systematic review of current evidence. Ecancer Med Sci 14:1022. Published 27 Mar 2020</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7105343</ArticleId><ArticleId IdType="pubmed">32256705</ArticleId></ArticleIdList></Reference><Reference><Citation>Tian S, Hu W, Niu L, Liu H, Xu H, Xiao SY (2020) Pulmonary pathology of early-phase 2019 novel coronavirus (COVID-19) pneumonia in two patients with lung cancer [published online ahead of print, 2020 Feb 28]. J Thorac Oncol S1556&#x2013;0864(20)30132&#x2013;5</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7128866</ArticleId><ArticleId IdType="pubmed">32114094</ArticleId></ArticleIdList></Reference><Reference><Citation>Russell B, Moss C, George G et al (2020) Associations between immune-suppressive and stimulating drugs and novel COVID-19-a systematic review of current evidence. Ecancer Med Sci 14:1022. Published 27 Mar 2020</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7105343</ArticleId><ArticleId IdType="pubmed">32256705</ArticleId></ArticleIdList></Reference><Reference><Citation>NIHR (2020) Living with covid-19. A dynamic review of the evidence around ongoingcovid-19 symptoms (often called long covid).&#xa0;https://evidence.nihr.ac.uk/themedreview/living-with-covid19</Citation></Reference><Reference><Citation>https://www.uptodate.com/contents/coronavirus-disease-2019-covid-19-critical-care-issues</Citation></Reference><Reference><Citation>Matuschak GM, Lechner AJ (2010) Acute lung injury and the acute respiratory distress syndrome: pathophysiology and treatment. Mo Med 107(4):252&#x2013;258</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6188356</ArticleId><ArticleId IdType="pubmed">20806836</ArticleId></ArticleIdList></Reference><Reference><Citation>Walkey AJ, Summer R, Ho V, Alkana P (2012) Acute respiratory distress syndrome: epidemiology and management approaches. Clin Epidemiol 4:159&#x2013;169</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3410685</ArticleId><ArticleId IdType="pubmed">22866017</ArticleId></ArticleIdList></Reference><Reference><Citation>Williams AE, Chambers RC (2014) The mercurial nature of neutrophils: still an enigma in ARDS?. Am J Physiol Lung Cell Mol Physiol 306(3):L217&#x2013;L230</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3920201</ArticleId><ArticleId IdType="pubmed">24318116</ArticleId></ArticleIdList></Reference><Reference><Citation>Burnham EL, Janssen WJ, Riches DW, Moss M, Downey GP (2014) The fibroproliferative response in acute respiratory distress syndrome: mechanisms and clinical significance. Eur Respir J 43(1):276&#x2013;285</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4015132</ArticleId><ArticleId IdType="pubmed">23520315</ArticleId></ArticleIdList></Reference><Reference><Citation>Kouzbari K, Hossan MR, Arrizabalaga JH et al&#xa0;(2019) Oscillatory shear potentiates latent TGF-&#x3b2;1 activation more than steady shear as demonstrated by a novel force generator. Sci Rep 9, 6065</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6465594</ArticleId><ArticleId IdType="pubmed">30988341</ArticleId></ArticleIdList></Reference><Reference><Citation>Johannson K, Collard HR (2013) Acute exacerbation of idiopathic pulmonary fibrosis: a proposal. Curr Respir Care Rep2(4):10.1007/s13665-013-0065-x</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3883625</ArticleId><ArticleId IdType="pubmed">24416637</ArticleId></ArticleIdList></Reference><Reference><Citation>Raghu G, Collard HR, Egan JJ, Martinez FJ, Behr J, Brown KK, Colby TV, Cordier JF, Flaherty KR, Lasky JA, Lynch DA, Ryu JH, Swigris JJ, Wells AU, Ancochea J, Bouros D, Carvalho C, Costabel U, Ebina M, Hansell DM, Johkoh T, Kim DS, King TE Jr, Kondoh Y, Myers J, M&#xfc;ller NL, Nicholson AG, Richeldi L, Selman M, Dudden RF, Griss BS, Protzko SL, Sch&#xfc;nemann HJ (2011) ATS/ERS/JRS/ALAT Committee on Idiopathic Pulmonary Fibrosis. An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management. Am J Respir Crit Care Med 183(6):788</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5450933</ArticleId><ArticleId IdType="pubmed">21471066</ArticleId></ArticleIdList></Reference><Reference><Citation>Herridge MS, Tansey CM, Matt&#xe9; A, Tomlinson G, Diaz-Granados N, Cooper A et al (2011) Functional disability 5 years after acute respiratory distress syndrome. N Engl J Med 364(14):1293&#x2013;1304</Citation><ArticleIdList><ArticleId IdType="pubmed">21470008</ArticleId></ArticleIdList></Reference><Reference><Citation>Bansal M (2020) Cardiovascular disease and COVID-19. Diabetes Metab Syndr 14(3):247&#x2013;250</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7102662</ArticleId><ArticleId IdType="pubmed">32247212</ArticleId></ArticleIdList></Reference><Reference><Citation>Vaidya A, Dluhy R (2000) Hyperaldosteronism. [Updated 2016 Oct 19]. In: Feingold KR, Anawalt B, Boyce A, et al., editors. Endotext [Internet]. South Dartmouth (MA): MDText.com, Inc. Available from: https://www.ncbi.nlm.nih.gov/books/NBK279065/</Citation></Reference><Reference><Citation>Young BE, Ong SWX, Kalimuddin S et al (2020) Epidemiologic features and clinical course of patients infected with SARS-CoV-2 in Singapore. JAMA ([Internet]. Available from:): 1&#x2013;7</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7054855</ArticleId><ArticleId IdType="pubmed">32125362</ArticleId></ArticleIdList></Reference><Reference><Citation>Yao X, Ye F, Zhang M, Cui C, Huang B, Niu P, Liu X, Zhao L, Dong E, Song C, Zhan S, Lu R, Li H, Tan W, Liu D (2020) In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). Clin Infect Dis</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7108130</ArticleId><ArticleId IdType="pubmed">32150618</ArticleId></ArticleIdList></Reference><Reference><Citation>Soubrier M, Pei J, Durand F, Gullestad L, John A (2017) Concomitant Use of Statins in Tocilizumab-Treated Patients with Rheumatoid Arthritis: A Post Hoc Analysis. Rheumatol Ther Jun;4(1):133-149</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5443718</ArticleId><ArticleId IdType="pubmed">27900570</ArticleId></ArticleIdList></Reference><Reference><Citation>Tan W, Aboulhosn J (2020) The cardiovascular burden of coronavirus disease 2019 (COVID-19) with a focus on congenital heart disease [published online ahead of print, 2020 Mar 28]. Int J Cardiol S0167&#x2013;5273(20)31593-X</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7102656</ArticleId><ArticleId IdType="pubmed">32248966</ArticleId></ArticleIdList></Reference><Reference><Citation>Biernacka A, Frangogiannis NG (2011) Aging and Cardiac Fibrosis. Aging Dis 2(2):158&#x2013;173</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3153299</ArticleId><ArticleId IdType="pubmed">21837283</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu Q, Zhou L, Sun X (2017) Altered lipid metabolism in recovered SARS patients twelve years after infection. Sci Rep 7:9110</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5567209</ArticleId><ArticleId IdType="pubmed">28831119</ArticleId></ArticleIdList></Reference><Reference><Citation>Giacomelli A, Pezzati L, Conti F et al (2020) Self-reported olfactory and taste disorders in SARS-CoV-2 patients: a cross-sectional study. Clin Infect Dis. [epub ahead of print]</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7184514</ArticleId><ArticleId IdType="pubmed">32215618</ArticleId></ArticleIdList></Reference><Reference><Citation>Mao L, Jin H, Wang M, Hu Y, Chen S, He Q, Chang J, Hong C, Zhou Y, Wang D, Miao X, Li Y, Hu B (2020) Neurologic Manifestations of Hospitalized Patients With Coronavirus Disease 2019 in Wuhan, China. JAMA Neurol</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7149362</ArticleId><ArticleId IdType="pubmed">32275288</ArticleId></ArticleIdList></Reference><Reference><Citation>Fern&#xe1;ndez-Klett F, Priller J (2014) The fibrotic scar in neurological disorders. Brain Pathol 24(4):404-13</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8029481</ArticleId><ArticleId IdType="pubmed">24946078</ArticleId></ArticleIdList></Reference><Reference><Citation>Gawlytta R, Niemeyer H, B&#xf6;ttche M, Scherag A, Knaevelsrud C, Rosendahl J (2017) Internet-based cognitive-behavioural writing therapy for reducing post-traumatic stress after intensive care for sepsis in patients and their spouses (REPAIR): study protocol for a randomised-controlled trial. BMJ Open 7(2):e014363</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5337733</ArticleId><ArticleId IdType="pubmed">28232467</ArticleId></ArticleIdList></Reference><Reference><Citation>Annane D, Sharshar T (2015) Cognitive decline after sepsis. Lancet Respir Med 3(1):61&#x2013;9</Citation><ArticleIdList><ArticleId IdType="pubmed">25434614</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu, Yeshun, Xu X, Chen Z, Duan J, Hashimoto K, Yang L, Liu C, Yang C (2020) Nervous system involvement after infection with COVID-19 and other coronaviruses. Brain. Behav. Immun. 10.1016/j.bbi.2020.03.031</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7146689</ArticleId><ArticleId IdType="pubmed">32240762</ArticleId></ArticleIdList></Reference><Reference><Citation>Troyer EA, Kohn JN, Hong S (2020) Are we facing a crashing wave of neuropsychiatric sequelae of COVID-19? Neuropsychiatric symptoms and potential immunologic mechanisms [published online ahead of print, 2020 Apr 13]. Brain Behav Immun S0889&#x2013;1591(20)30489-X</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7152874</ArticleId><ArticleId IdType="pubmed">32298803</ArticleId></ArticleIdList></Reference><Reference><Citation>Kashima R, Akiko Hata A (2018) The role of TGF-&#x3b2; superfamily signaling in neurological disorders. Acta Biochimica et Biophysica Sinica 50(1):106&#x2013;120</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5846707</ArticleId><ArticleId IdType="pubmed">29190314</ArticleId></ArticleIdList></Reference><Reference><Citation>Klok FA, Kruip MJHA, van der Meer NJM et al (2020) Incidence of thrombotic complications in critically ill ICU patients with COVID-19 [published online ahead of print, 2020 Apr 10]. Thromb Res S0049&#x2013;3848(20)30120&#x2013;1</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7146714</ArticleId><ArticleId IdType="pubmed">32291094</ArticleId></ArticleIdList></Reference><Reference><Citation>Mao L, Wang M, Chen S, He O, Chang J et al (2020)Neurological manifestations of hospitalized patients with COVID-19 in Wuhan, China: a retrospective case series study. medRxiv 02.22.20026500</Citation></Reference><Reference><Citation>Horiguchi H, Loftus TJ, Hawkins RB et al (2018) Innate immunity in the persistent inflammation, immunosuppression, and catabolism syndrome and its implications for therapy. Front Immunol 9:595. Published 4 Apr 2018</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5893931</ArticleId><ArticleId IdType="pubmed">29670613</ArticleId></ArticleIdList></Reference><Reference><Citation>Parichatikanond W, Luangmonkong T, Mangmool S, Kurose H (2020) Therapeutic targets for the treatment of cardiac fibrosis and cancer: focusing on TGF-&#x3b2; signaling. Front Cardiovasc Med 7:34. Published 10 Mar 2020</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7075814</ArticleId><ArticleId IdType="pubmed">32211422</ArticleId></ArticleIdList></Reference><Reference><Citation>Allahwala UK, Denniss AR, Zaman S, Bhindi R (2020) Cardiovascular disease in the post-COVID-19 era &#x2013; the impending tsunami? [published online ahead of print, 2020 Apr 16]. Heart Lung Circ</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7161486</ArticleId><ArticleId IdType="pubmed">32371032</ArticleId></ArticleIdList></Reference><Reference><Citation>Das N (2020) Psychiatrist in post-COVID-19 era - Are we prepared? [published online ahead of print, 2020 Apr 7]. Asian J Psychiatr 51:102082</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7139240</ArticleId><ArticleId IdType="pubmed">32283513</ArticleId></ArticleIdList></Reference><Reference><Citation>McInnes IB (2020) COVID-19 and rheumatology: first steps towards a different future? Annals Rheumatic Diseases 79:551-552</Citation><ArticleIdList><ArticleId IdType="pubmed">32299844</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>